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Abstract: Radiomics is an exciting new area of texture research 
for extracting quantitative and morphological characteristics of 
pathological tissue. However, to date, only single images have been 
used for texture analysis.  We have extended radiomic texture 
methods to use multiparametric (mp) data to get more complete 
information from all the images.  These mpRadiomic methods 
could potentially provide a platform for stratification of tumor 
grade as well as assessment of treatment response in brain tumors.  
In brain, multiparametric MRI (mpMRI) are based on contrast 
enhanced T1-weighted imaging (T1WI), T2WI, Fluid Attenuated 
Inversion Recovery (FLAIR), Diffusion Weighted Imaging (DWI) 
and Perfusion Weighted Imaging (PWI).  Therefore, we applied 
our multiparametric radiomic framework (mpRadiomic) on 24 
patients with brain tumors (8 grade II and 16 grade IV).  The 
mpRadiomic framework classified grade IV tumors from grade II 
tumors with a sensitivity and specificity of 93% and 100%, 
respectively, with an AUC of 0.95.  For treatment response, the 
mpRadiomic framework classified pseudo-progression from true-
progression with an AUC of 0.93. In conclusion, the mpRadiomic 
analysis was able to effectively capture the multiparametric brain 
MRI texture and could be used as potential biomarkers for 
distinguishing grade IV from grade II tumors as well as 
determining true-progression from pseudo-progression. 
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I. INTRODUCTION 
rain cancer is a major health problem in the United States. 
According to estimates from the American Brain Tumor 
Association & Central Brain Tumor Registry of the United 
States, there is an annual incidence of nearly 80,000 new cases 
of primary brain tumors in the U.S. In addition, the estimated 
annual mortality from primary malignant CNS tumors is 
approximately 17,000 1. Despite advances in structural and 
physiologic magnetic resonance imaging (MRI), positron 
emission tomography (PET) and other nuclear medicine 
imaging techniques and molecular genetics, impact on overall 
mortality and morbidity, particularly for high grade gliomas, 
remains dismal; the 5-year survival for glioblastoma patients is 
15-20% despite maximal safe resection, chemotherapy with 
temozolomide and radiation treatment. Moreover, no 
therapeutic options provide substantial survival benefit for 
recurrent disease 2-4. 
Although there have been advances in radiological imaging 
of human brain tumors (structural MRI, diffusion and perfusion 
MRI, MR spectroscopic imaging (MRS), PET, task and resting 
state BOLD), reliable utility has only been established in 
noninvasive grading of de novo tumors 5.  
However, distinguishing between true progression and 
pseudoprogression in high grade gliomas remains a clinical 
challenge and is frequently accomplished only through surgical 
biopsy/resection and not noninvasively 6-10.  Need for better 
imaging assessment of progressive vs. stable disease led to the 
development of the recent RANO (Response Assessment in 
Neuro-Oncology) criteria11-13, but even these new imaging 
criteria do not allow accurate and early differentiation between 
true therapeutic response and pseudoresponse  or between true 
progression and pseudoprogression; even metabolic and 
physiologic imaging such as PET, MR spectroscopy and amide 
proton transfer imaging have not been entirely reliable for such 
differentiation.  Furthermore, neither perfusion imaging nor 
MRS is 100% specific in distinguishing true progression from 
pseudoprogression or actual treatment response from 
pseudoresponse in high grade gliomas. 6-10.  The need for 
standardization and validation of conventional MR imaging 
determinants of therapeutic response has led to development of 
the recent Response Assessment in Neuro-Oncology (RANO) 
criteria 9,13.  Moreover, a recent 2016 update to the earlier 2007 
WHO classification system, now includes molecular markers, 
such as isocitrate dehydrogenase gene (IDH1) mutation status, 
ATP-dependent helicase (ATRX), Telomerase reverse 
transcriptase (TERT), TP53, 1p/19q co-deletion, O6-
methylguanine-DNA methyltransferase (MGMT) methylation 
status and EGFR expression in the definition of glioma 
subtypes based on prognostic factors and treatment 
responsiveness14-18. Furthermore, no currently available 
imaging biomarkers exist to reliably predict transformation to 
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higher grades from low grade gliomas. 
In recent years, radiomics has been applied to many different 
precision medicine and radiology applications in the research 
setting with great preliminary results 14,19-22. However, 
radiomics was initially developed for application to single 
radiological images and may not characterize high dimensional 
datasets such as multiparametric brain MRI effectively. 
Recently, we developed the multiparametric radiomics 
(mpRadiomic) framework to extend the single radiomics 
framework for application to multiparametric radiological 
imaging setting with excellent results 23. Here, we implement 
the mpRadiomic framework for application to brain mpMRI 
and evaluate its efficacy in brain tumor grading and treatment 
response assessment.   
II. METHODS AND MATERIALS 
Clinical Parameters: Twenty-four patients with brain tumors 
were imaged in this retrospective study. There were 13 males 
and 11 females, with average age of 51±15 years.  For 
therapeutic monitoring, eight patients with grade IV 
glioblastoma were imaged for assessment of treatment response 
and tumor progression.  Histological and genomic profile 
markers were recorded.  The molecular markers were isocitrate 
dehydrogenase gene (IDH1) mutation status, ATP-dependent 
helicase (ATRX), TP53, 1p/19q co-deletion, O6-
methylguanine-DNA methyltransferase (MGMT) methylation 
status. 
MRI Sequences: MR images were obtained using a 3.0 Tesla 
Siemens Trio Tim system (Siemens Medical Solutions, 
Erlangen, Germany) with transmit/receive head matrix coil.  
Anatomical Sequences: Structural images included a 3D T1 
MPRAGE sequence (TR = 2300ms, TI = 900ms, TE = 3.5ms, 
flip angle = 9°, field of view = 24cm, acquisition matrix = 256 
x 256 x 176, slice thickness (ST) = 1mm) and a 2D T2-FLAIR 
axial sequence (TR=9310 ms, TI=2500 ms, TE=116 ms, flip 
angle = 141°, field of view = 24cm, acquisition matrix = 320 x 
240 x 50, ST= 3 mm).  
Perfusion and Diffusion Sequences: Perfusion Weighted 
Imaging: Whole brain single-shot GRE EPI sequence after 
administration of 0.1mmol/kg of a gadolinium-based contrast 
agent was acquired with parameters as follow: 
TR/TE=2450/45ms; 90º deg flip angle; FOV=240x240mm 
128x128 matrix; ST=4mm with 1 mm interslice gap; 32 
volumes acquired with first 2 discarded to allow MR signal to 
reach steady state. 
Diffusion Weighted Imaging: Diffusion tensor imaging was 
obtained using spin echo EPI parallel imaging sequence 
TR/TE=6700/90, 90º flip angle, 192x192mm FOV, 96x 96 
matrix, 3mm, 20 directions of diffusion encoding, and b values 
= 0 and 1000 s/mm2.  Trace monoexponentially Apparent 
Diffusion Coefficient (ADC) of water maps were constructed 
from the DWI. 
Registration methods: For accurate co-localization, we have 
developed a hybrid registration method based on a combined 
3D wavelet transformation with nonlinear affine transformation 
that performs 3D resampling and interpolations of the reference 
and target radiological images without a loss of information 24. 
The hybrid registration scheme consists of reslicing and 
matching each modality using a combination of wavelet and 
affine registration steps. First, orthogonal reslicing is performed 
to equalize the FOV, matrix sizes, and the number of slices 
using a wavelet transformation between the data sets, then 
followed by angular resampling of the target data to match the 
reference data set.  Finally, using the optimized angles from 
resampling, the registration is performed based on the similarity 
transformation between the reference volume and the resliced 
target volume.  For each data set, the mean square error and 
Dice similarity measures were calculated. 
Segmentation methods: We segmented the normal tissue 
(WM, GM and CSF) and the lesion tissue from multiparametric 
MRI using the multiparametric deep learning tissue signature 
model (MPDL) 25. The MPDL is based on stacked sparse 
autoencoders (SSAE), which combines unsupervised pre-
training with supervised fine tuning to counter the sparsity in 
the training labels. The tumor segmentation was performed in a 
semi-supervised fashion, where-in few pixels corresponding to 
every tissue type were labeled for each patient followed by 
subsequent training and segmentation using MPDL26-28. 
Multiparametric Radiomics Framework: The textural and 
shape properties of the brain tumor were defined by the 
mpRadiomics features based on tissue signature probability 
matrix (TSPM) and the tissue signature co-occurrence matrix 
(TSCM) which are basically the extensions of the first order 
statistics and gray level co-occurrence matrix-based features 
extracted from single images 19. The input parameters for 
mpRadiomics analysis were determined using empirical 
analysis based on image resolution as follows: 
a. Binning for TSPM = 64 
b. Gray level quantization for TSCM = 64 
c. The distance d for TSCM was set to one voxel. 
d. The TSCM was evaluated in all the four directions – 
0°,45°,90° and 135°.  
The binning and gray level quantization for the task of 
distinguishing true-progression from pseudo-progression was 
set to 16 because of the lower image resolution of the perfusion 
MRI compared to the important MRI parameters (FLAIR, T1-
 
Fig. 1.  A) Example multiparametric MRI from a Grade IV tumor with the 
post contrast enhanced T1 image displaying the perirolandic lesion (Yellow 
Box). B) Single radiomic images from each of the MRI parameters. C) 
Multiparametric radiomics of all the MRI data together demonstrating 
improved tissue characteristics. 
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Pre and T1-Post contrast) used for distinguishing between grade 
II from grade IV brain tumors.  
 
The Radiomic Tissue Signature Model: We define a tissue 
signature (TS) that represents a composite feature 
representation of a tissue type based on each of the different 
imaging sequences and demonstrated in Fig. 1. Mathematically, 
for N different imaging parameters with TS at a voxel position, 
Sp is defined as a vector of gray level intensity values at that 
voxel position, p across all the (N) images in the data sequence 
for different tissue types and is given by the following equation, 
𝑆𝑝 =  [𝐼𝑝
(1), 𝐼𝑝
(2), 𝐼𝑝
(3),  … , 𝐼𝑝
(𝑁)]
𝑇
(1) 
Where, Ip is the intensity at voxel position, p on each image. 
 
The Tissue signature probability matrix features 
The tissue signature probability matrix (TSPM) characterizes 
the spatial distribution of tissue signatures within a ROI. The 
mathematical formulation of TSPM is defined as: Suppose that 
the intensity values representing each voxel are quantized to 
some G level, then the total number of possible tissue signatures 
in a dataset consisting of N images will be equal to 𝐺𝑁. We 
define a function 𝑓: 𝑇 → 𝑀, where T is the set of all tissue 
signatures in the dataset and M is a N dimensional matrix with 
edges of length G where each tissue signature is represented as 
a cell. The function f populates each cell of the matrix M with 
the frequency of occurrence of the corresponding tissue 
signature in the set T. The resulting matrix M is called the tissue 
signature probability matrix (TSPM).  The information content 
of the N dimensional multiparametric imaging dataset 
(𝑋1, 𝑋2, … 𝑋𝑁) can be analyzed by computing the joint entropy, 
uniformity, and mutual information of the resultant TSPM29.  
These features are defined below. 
 
1. The TSPM entropy, H is given by the following equation: 
𝐻(𝑋1, 𝑋2, … 𝑋𝑁) =
 − ∑ ∑ … ∑ 𝑇𝑆𝑃𝑀(𝑖1, 𝑖2, … , 𝑖𝑁) log2 𝑇𝑆𝑃𝑀(𝑖1, 𝑖2, … , 𝑖𝑁)
𝑁𝑔
𝑖𝑁=1
𝑁𝑔
𝑖2=1
𝑁𝑔
𝑖1=1
  
2. The TSPM uniformity, U is given by the following equation 
𝑈(𝑋1, 𝑋2, … 𝑋𝑁) =  ∑ ∑ … ∑ 𝑇𝑆𝑃𝑀(𝑖1, 𝑖2, … , 𝑖𝑁)
2𝑁𝑔
𝑖𝑁=1
𝑁𝑔
𝑖2=1
𝑁𝑔
𝑖1=1
  (3) 
3. The TSPM mutual information, MI is given by 
𝑀𝐼(𝑋1; 𝑋2; … ; 𝑋𝑁) = (𝐻(𝑋1) + 𝐻(𝑋2) + ⋯ + 𝐻(𝑋𝑁)) −
⋯ + ⋯ (−1)𝑁−1𝐻(𝑋1, 𝑋2, … , 𝑋𝑁) (4) 
By choosing different possible subsets 𝑌 ⊆ {𝑋1, 𝑋2, … , 𝑋𝑁} 
and different values of H(Y), U(Y) and MI(Y) can be obtained 
producing a large number of mpRad features. 
 
Tissue signature first order statistics features: The tissue 
signature first order statistics (TSFOS) features characterize the 
distribution of voxel intensities across all the imaging 
parameters. This is similar to a traditional first order histogram, 
except, the TSFOS histogram is computed from the voxel 
intensities across all the imaging parameters, which can be very 
useful when analyzing multiparametric imaging sequences such 
DWI and PWI. Let the Tissue Signature Histogram (𝑇𝑆𝐻) 
represent a TSFOS histogram that is computed by dividing the 
voxel intensities in mpMRI into B equally spaced bins. The first 
order statistical features (e.g. entropy) can be computed from 
the 𝑇𝑆𝐻 using the following equation: 
𝐸𝑛𝑡𝑟𝑜𝑝𝑦𝑇𝑆𝐹𝑂𝑆 =  − ∑ 𝑇𝑆𝐻(𝑖) log 𝑇𝑆𝐻(𝑖)
𝐵
𝑖=1    (5) 
 
The remaining TSFOS features, such as uniformity and 
energy, are similarly derived from TSH.  
Tissue signature co-occurrence matrix features 
The tissue signature co-occurrence matrix (TSCM) 
characterizes the spatial relationship between tissue signatures 
within a ROI. The TSCM is defined similar to the gray level co-
occurrence matrix (GLCM) using two input parameters, 
distance (d) and angle (𝜃) between two tissue signature 
locations 30,31. Mathematically, the GLCM between any two 
tissue signatures, Si and Sj is given by the following equation 
 
𝐺𝐿𝐶𝑀𝑑
𝜃(𝑆𝑖, 𝑆𝑗 , 𝑚, 𝑛) = |{𝑟 ∶ 𝑆𝑖(𝑟) = 𝑚, 𝑆𝑗(𝑟) = 𝑛}| ∀ 𝑚, 𝑛 𝜖{1,2,3, … , 𝐺} (6)
 where  𝑟 ∈ 𝑁 (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑚𝑎𝑔𝑖𝑛𝑔 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠) and | . | 
denotes the cardinality of a set.  
Given a distance, d and angle, (𝜃), the TSCM co-occurrence 
matrix for all such possible pairs of tissue signatures is given 
as follows: 
𝑇𝑆𝐶𝑀𝑑
𝜃( 𝑚, 𝑛) = Σ𝑖,𝑗𝐺𝐿𝐶𝑀𝑑
𝜃(𝑆𝑖 , 𝑆𝑗 , 𝑚, 𝑛) 
∀ 𝑖, 𝑗 𝑠𝑎𝑡𝑖𝑠𝑓𝑖𝑒𝑑 𝑏𝑦 𝑑 𝑎𝑛𝑑 𝜃   (7) 
Here, 𝑇𝑆𝐶𝑀𝑑
𝜃  is the tissue signature co-occurrence matrix. The 
TSCM can then be analyzed to extract twenty-two different 
TSCM features using the equations developed by Haralick et 
al30.  
Classification: The patients were classified using the IsoSVM 
algorithm 32. The IsoSVM classification algorithm is an 
extension of the linear binary SVM algorithm, where in, the 
Isomap algorithm is pre-applied as a nonlinear kernel on the 
input dataset to transform the patients from a nonlinear space to 
a linear space.  We evaluated the efficacy of the IsoSVM 
algorithm in classifying grade II from grade IV tumors using 
leave one out cross validation. 
Statistical analysis: Summary statistics (mean and standard 
error of the mean) were recorded for the radiomic features. 
Student’s t-test was performed to compare the grade II, grade 
IV and normal volunteers. We computed the area under the 
receiver operating characteristic (ROC) curve (AUC) for each 
of the radiomic features.  Differences in the mpRadiomic 
features between two different time points were used to 
distinguish true from pseudo-progression using the Student’s t-
test.  Statistical significance was set at p<0.05. 
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III. RESULTS 
Tumor cases: Twenty-four patients (13 males, 11 females) 
with brain tumors were scanned.  There was no age difference 
(age range 27-75 years; mean 51.0, SD 15.01). Of the 24 cases, 
there were 9 (37.5%) Grade II and 15 (62.5%) Grade IV tumors. 
Grade II vs Grade IV: The texture analysis of tumors of grade 
II and IV patients demonstrated that grade II tumors had a 
significantly different texture signature than grade IV tumors.  
For example, grade II tumors had a significantly lower contrast 
than grade IV tumors, owing to the presence of necrotic region 
in grade IV tumors (TSCM contrast G2: 4.90±0.48, G4: 
15.19±0.2.18, p < 0.001).). In addition, grade II tumors were 
significantly more homogeneous than grade IV tumors (TSCM 
homogeneity G2: 0.57±0.01, G4: 0.49±0.01, p < 0.001). These 
features have been summarized in Table 1. Figure 2A 
demonstrates the TSCM mpRadiomic images on an example 
grade II and a grade IV patient. The IsoSVM algorithm using 
leave-one-out cross validation achieved a sensitivity and 
specificity of 93% and 100%, respectively, with an AUC of 
0.95. The two-dimensional space obtained using Isomap 
applied to the high dimensional mpRadiomic feature space is 
shown in Figure 2(B) and the ROC curve for the IsoSVM 
classifier has been shown in Figure 2(C).  
True progression vs. Pseudoprogression: Fig. 3 demonstrates 
our mpRadiomic analysis for differentiation of true progression 
(TP) from pseudo-progression (PP) in two representative WHO 
grade IV (glioblastoma) patients. There was a significant 
difference between the ADC map values of TP and PP.   The 
top radiomic features of TP and PP were identified as TSCM 
IMC1, TSCM Correlation, TSPM entropy, and TSPM 
uniformity and summarized in Table 2.  
The ROC curves for comparison between single and 
multiparametric radiomic features in distinguishing true from 
pseudo-progression tumors are shown Fig. 4. 
IV. DISCUSSION 
The multiparametric radiomics produced excellent features for 
the classification of WHO grade II from grade IV brain tumors 
and on distinguishing true from pseudo progression after 
chemoradiation. WHO grade IV tumors are characterized by the  
T1-weighted images following gadolinium administration and 
the presence of a necrotic core, when there is no enhancement 
in WHO grade II tumors. We observed that WHO grade IV 
tumors had mpRadiomic features of increased heterogeneity 
(entropy, mutual information, homogeneity) compared to grade 
II tumors.    In addition, WHO grade IV tumors had a higher 
TSCM contrast than WHO grade II tumors. The higher 
heterogeneity and TSCM contrast could characterize the 
presence of more aggressive cancer in these tumors.  Single 
image radiomics has been previously shown to characterize 
brain tumors in previous studies20,21,33-35. However, this study 
evaluated the efficacy of mpRadiomic features that integrates 
all the mpMRI parameters to produce unique radiomic features 
 
Fig. 2  A) Example grade II and grade IV patients with the multiparametric 
MRI images and the corresponding multiparametric radiomics 
(mpRadiomic) TSCM features of informational measure of correlation 1, 
contrast and entropy. B) Patient scattergram demonstrating the grade II and 
grade IV patients in a two-dimensional space transformed by applying 
Isomap on the high dimensional mpRadiomic space. C) The receiver 
operating characteristic curve (ROC) corresponding to the IsoSVM 
algorithm applied on the mpRadiomic features for classification of grade 
II from grade IV tumors. The AUC was 0.95. 
 
 
 
Fig. 3 Demonstration of mpRadiomics differentiation between true from 
pseudo-progression of two patients with WHO Grade IV gliomas that 
received chemoradiation.  Top Two Rows) A patient with a right temporal 
lobe mass at two-time points TP-1 and TP-2 demonstrating true 
progression.  Bottom Two Rows) A patient with left temporal lobe 
glioblastoma at two time points with pseudo-progression (PP-1 and PP-2). 
Table 1. Summary of the multiparametric radiomic tissue signature  
co-occurrence matrix (TSCM) features for classification of grade II from 
grade IV brain tumors.   
 
mpRadomic Feature Grade II Grade IV p value 
Contrast 4.90±0.48 15.19±2.18 0.0003 
Correlation 0.97±0.01 0.84±0.03 0.0003 
Entropy 5.26±0.11 5.52±0.12 0.13 
Homogeneity1 0.57±0.01 0.49±0.01 0.00005 
Informational measure of 
correlation 1 
0.42±0.01 -0.28±0.02 p<0.00001 
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for the prediction of brain tumor grade. 
 Preliminary analysis on distinguishing true from pseudo- 
progression demonstrated that the mpRadiomic features could 
provide higher classification accuracy than single parameter 
radiomic features. The mpRadiomic features of true 
progression had a different tissue texture types than the pseudo- 
progression cases. This distinction could be helpful in 
determining the appropriate therapeutic choice for the patient.  
However, these mpRadiomic features would need to be 
validated in a larger patient cohort for stability and repeatability 
before these features could be used as biomarkers in the clinical 
setting. 
In general, mpMRI in brain produces a large number of 
images corresponding to each slice location, thereby producing 
a high dimensional image space. Extracting only single 
radiomic features from such datasets will not provide complete 
information about the tissue. The mpRadiomic approach 
resolves this issue by extracting intrinsic radiomic features of 
each tissue texture but also evaluates the overall tissue texture 
in all the images, giving a more complete picture of the tissue.  
There are some limitations in using mpRadiomics in practice 
specific to the present study.  This preliminary study was 
retrospective and any assessment of the clinical value of 
mpRadiomics will require additional prospective studies with 
subsequent follow-up and pathological correlation.   
 
 
V. CONCLUSION 
In conclusion, the mpRadiomic analysis was able to effectively 
capture the multiparametric brain MRI texture and 
demonstrated that it potentially could be used as an imaging 
biomarker for distinguishing WHO grade IV from grade II 
tumors and true-progression from pseudo-progression after 
chemoradiation therapy in brain cancer.  
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